The Heavy Metal Poisoning drugs in development market research report provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Heavy Metal Poisoning. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Heavy Metal Poisoning and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Heavy Metal Poisoning by seven companies/universities/institutes. The top development phase for Heavy Metal Poisoning is preclinical with six drugs in that stage. The Heavy Metal Poisoning pipeline has six drugs in development by companies and two by universities/ institutes. Some of the companies in the Heavy Metal Poisoning pipeline products market are: Medesis Pharma, University of Nantes and Dana-Farber Cancer Institute.

The key targets in the Heavy Metal Poisoning pipeline products market include Iron, Lead, and Mercury.

The key mechanisms of action in the Heavy Metal Poisoning pipeline product include Iron Chelator with two drugs in Preclinical. The Heavy Metal Poisoning pipeline products include four routes of administration with the top ROA being Buccal and one key molecule types in the Heavy Metal Poisoning pipeline products market including Small Molecule.

Heavy Metal Poisoning overview

Heavy metal poisoning is the accumulation of heavy metals in toxic amounts in the soft tissues of the body. Sources of toxicity can include environmental, water supply, industrial exposure, and hobbies. Symptoms include headaches, drowsiness, confusion, seizures, nausea, vomiting, abdominal cramps, tinnitus, goiter, anorexia, and diarrhea. Treatment includes chelation therapy.

For a complete picture of Heavy Metal Poisoning’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.